Jim Simons’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.76M | Sell |
1,344,829
-780,271
| -37% | -$1.08M | ﹤0.01% | 2036 |
|
|
2026
Q1 | $3.36M | Sell |
2,125,100
-279,700
| -12% | -$472K | 0.01% | 1599 |
|
|
2025
Q4 | $4.02M | Buy |
2,404,800
+499,167
| +26% | +$864K | 0.01% | 1433 |
|
|
2025
Q3 | $3.22M | Sell |
1,905,633
-66,702
| -3% | -$78.9K | ﹤0.01% | 1743 |
|
|
2025
Q2 | $1.79M | Sell |
1,972,335
-319,046
| -14% | -$189K | ﹤0.01% | 2179 |
|
|
2025
Q1 | $1.03M | Buy |
2,291,381
+8,309
| +0.4% | +$4.87K | ﹤0.01% | 2409 |
|
|
2024
Q4 | $1.15M | Buy |
2,283,072
+2,085,972
| +1,058% | +$1.53M | ﹤0.01% | 2422 |
|
|
2024
Q3 | $178K | Sell |
197,100
-386,522
| -66% | -$358K | ﹤0.01% | 3146 |
|
|
2024
Q2 | $582K | Buy |
583,622
+53,022
| +10% | +$58.6K | ﹤0.01% | 2625 |
|
|
2024
Q1 | $785K | Buy |
530,600
+380,600
| +254% | +$432K | ﹤0.01% | 2639 |
|
|
2023
Q4 | $164K | Buy |
150,000
+90,300
| +151% | +$98.9K | ﹤0.01% | 3193 |
|
|
2023
Q3 | $70K | Buy |
59,700
+3,800
| +7% | +$5.17K | ﹤0.01% | 3321 |
|
|
2023
Q2 | $79K | Buy |
+55,900
| New | +$77.2K | ﹤0.01% | 3520 |
|
|
2021
Q1 | – | Sell |
-23,000
| Closed | -$40K | – | 3532 |
|
|
2020
Q4 | $40K | Sell |
23,000
-437,806
| -95% | -$612K | ﹤0.01% | 3327 |
|
|
2020
Q3 | $432K | Sell |
460,806
-30,894
| -6% | -$27.3K | ﹤0.01% | 2867 |
|
|
2020
Q2 | $428K | Buy |
491,700
+223,300
| +83% | +$197K | ﹤0.01% | 2924 |
|
|
2020
Q1 | $222K | Buy |
+268,400
| New | +$267K | ﹤0.01% | 3077 |
|
|
2019
Q1 | – | Sell |
-259,300
| Closed | -$237K | – | 3587 |
|
|
2018
Q4 | $237K | Buy |
+259,300
| New | +$397K | ﹤0.01% | 3092 |
|
|
2018
Q3 | – | Sell |
-166,421
| Closed | -$300K | – | 3459 |
|
|
2018
Q2 | $300K | Sell |
166,421
-721,004
| -81% | -$1.45M | ﹤0.01% | 2960 |
|
|
2018
Q1 | $2.09M | Sell |
887,425
-481,660
| -35% | -$1.13M | ﹤0.01% | 2306 |
|
|
2017
Q4 | $2.58M | Buy |
1,369,085
+922,972
| +207% | +$2.02M | ﹤0.01% | 2190 |
|
|
2017
Q3 | $1.11M | Buy |
446,113
+302,544
| +211% | +$750K | ﹤0.01% | 2541 |
|
|
2017
Q2 | $396K | Buy |
143,569
+22,614
| +19% | +$63.2K | ﹤0.01% | 2827 |
|
|
2017
Q1 | $365K | Buy |
+120,955
| New | +$343K | ﹤0.01% | 2858 |
|
|
2015
Q3 | – | Sell |
-204,437
| Closed | -$599K | – | 3269 |
|
|
2015
Q2 | $599K | Buy |
+204,437
| New | +$793K | ﹤0.01% | 2668 |
|
|
2014
Q2 | – | Sell |
-64,057
| Closed | -$170K | – | 2876 |
|
|
2014
Q1 | $170K | Buy |
+64,057
| New | +$189K | ﹤0.01% | 2644 |
|
Other funds holding LCTX
Jim Simons's LCTX Position: Q2 2026 in Review
Jim Simons reduced its Lineage Cell Therapeutics (LCTX) stake by 37% in Q2 2026, selling an estimated $1.08M and leaving 1,344,829 shares worth $1.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2036.
Jim Simons first reported a position in LCTX in Q1 2014 and has held it in 26 quarters since. The position peaked at $4.02M in Q4 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Jim Simons held 1,344,829 shares of Lineage Cell Therapeutics worth $1.76M as of Q2 2026.
- Jim Simons sold 780,271 Lineage Cell Therapeutics shares in Q2 2026, an estimated $1.08M.
- Lineage Cell Therapeutics made up ﹤0.01% of Jim Simons's portfolio in Q2 2026, its #2036 holding.
- Jim Simons first reported a position in Lineage Cell Therapeutics in Q1 2014 and has held it in 26 quarters since.
- Jim Simons's Lineage Cell Therapeutics position peaked at $4.02M in Q4 2025.
- 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.